Viracta (VIRX) Operating Sales Margin

Public company logo of Viracta Therapeutics (VIRX)

Viracta Therapeutics (VIRX) relies on a sufficient liquidity reserve while awaiting the outcomes of clinical trials for its targeted therapies. Fluctuations in the operating margin reflect a lack of recurring revenue, as the business remains in the research and development stage. The project's success depends on the efficacy of EBV-tumor therapy and the response of lymphoma patients. The current 0.00 metric determines this level of financial stability.

VIRX: Viracta Therapeutics Operating Margin 07/04/2022 - 02/16/2025

Financial and market metric breakdowns for Viracta Therapeutics Inc. (VIRX)

- share price and consensus valuation forecast:
Fundamental company valuation:Viracta Therapeutics, VIRX
Brand item of Viracta Therapeutics, Inc.

The efficiency of Viracta Therapeutics (VIRX) international clinical trial logistics is reflected in the dynamics of its core operating profitability. This indicator is calculated as the ratio of operating profit before interest and taxes to total revenue, allowing for an assessment of the company's ability to generate cash flow from biologics while excluding the impact of capital structure and tax burdens.

Competitors of Viracta Therapeutics

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|PSNL: Operating Profitability|Erasca (ERAS) - Operating Profitability|DCTH - Profitability of Operations|YMAB (Y-mAbs Corp) - Operating Margin|Operating Sales Margin Aura Biosciences (AURA)|Operating Profitability Candel Therapeutics Inc. (CADL)|Operating Sales Margin Accuray, Inc. ARAY|Operating Profitability sellaslifesciences.com SLS|Operating Profit Rate ACTU|CTOR - Operating Profitability|Profitability of Operations tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operating Profitability|FATE: Operating Profit Ratio|WHWK (Aadi Bioscience, Inc.) - Operating Margin|TCRX (TScan Therapeutics) - Operating Profit Ratio|Operating Profitability Champions Oncology (CSBR)|Profitability of Operations XBiotech USA|Operating Profitability CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Operating Return on Sales|RADX - Operating Profitability|ARTV - Operating Margin|Adlai Nortye Ltd (ANL) - Operating Profitability|Veru Pharma - Operating Profit Rate|Operating Profitability Tempest Therapeutics Corp|Return on Sales by Operating Profit XLO (Xilio Therapeutics, Inc.)|Operating Margin RENB|MURA (Mural Oncology) - Operating Profit Rate|Operating Margin KAPA (Kairos Pharma Ltd)|OKUR: Return on Sales by Operating Profit|GDTC: Operating Sales Margin|CRIS - Operating Margin|APLM: Operating Margin|Operating Return on Sales tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Operating Margin|Operating Margin Genprex Inc.|Operating Margin CLDI|Operating Sales Margin Sunshine Biopharma, Inc. SBFM|Operating Margin XBIO (Xenetic Biosciences)|Operating Profit Rate SLRX|PPBT - Operating Profitability|AONC (aoncology.com) - Return on Sales by Operating Profit|BGNE: Operating Margin|Checkpoint Therapeutics Inc (CKPT) - Operating Margin|ELEV (Elevation Oncology Inc.) - Operating Margin|icadmed.com (ICAD) - Profitability of Operations|Operating Margin IKNA|NTBL (Notable Labs) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin